Kazia 
Welcome,         Profile    Billing    Logout  
 4 Products   115 Diseases  4 Products   10 Trials   577 News 
13 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
NV 52 / Kazia
SNV1521-101, NCT06220864: SNV1521 in Participants With Advanced Solid Tumors

Recruiting
1
76
US, RoW
SNV1521
Synnovation Therapeutics, Inc.
Advanced Solid Tumor
12/26
12/26
paxalisib (GDC-0084) / Kazia, SoVarGen, QIMR Berghofer Medical Research Institute
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Calendar Jan 2030 - Dec 2030: Market entry for glioblastoma
Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
NCT03522298: Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma

Checkmark Final data from P2 study in 1L glioblastoma at ESMO 2022
Sep 2022 - Sep 2022: Final data from P2 study in 1L glioblastoma at ESMO 2022
Checkmark Final data from trial for newly-diagnosed glioblastoma
Dec 2021 - Dec 2021: Final data from trial for newly-diagnosed glioblastoma
Completed
2
30
US
Paxalisib (GDC-0084)
Kazia Therapeutics Limited
Glioblastoma, Adult
03/23
03/23
NCT04906096: Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL

Hourglass Jan 2024 - Jun 2024 : Last-patient-in of P2 trial for primary CNS lymphoma
Hourglass Jul 2022 - Dec 2022 : Initial interim data from trial for primary CNS lymphoma
Recruiting
2
25
US
PAXALISIB, GDC-0084
Lakshmi Nayak, MD, Kazia Therapeutics Limited
Primary Central Nervous System Lymphoma, Non-Hodgkin Lymphoma of Extranodal Site
12/25
12/26
NCT03994796: Genetic Testing in Guiding Treatment for Patients with Brain Metastases

Recruiting
2
186
US
Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib, Adagrasib, MRTX849
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Mirati Therapeutics Inc., Genentech, Inc., Eli Lilly and Company, Kazia Therapeutics Limited
CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation, PI3K Gene Mutation, ROS1 Gene Mutation, KRAS G12C Mutation
10/26
06/28
NCT03765983: GDC-0084 in Combination with Trastuzumab for Patients with HER2-Positive Breast Cancer Brain Metastases

Hourglass Mar 2022 - Jun 2022 : Initial interim data from trial in combination with trastuzumab for Her2 +ve breast cancer brain metastases
Active, not recruiting
2
47
US
Trastuzumab, GDC-0084
Dana-Farber Cancer Institute, Kazia Therapeutics Limited
Breast Cancer
11/24
11/25
NCT05183204: Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma

Recruiting
2
33
US
Paxalisib, Metformin, Ketogenic Diet
Weill Medical College of Cornell University, Kazia Therapeutics Limited
Glioblastoma
12/24
12/25
NCT05009992: Combination Therapy for the Treatment of Diffuse Midline Gliomas

Hourglass Jun 2024 - Jul 2024 : Follow up data for DMG
Recruiting
2
360
Europe, US, RoW
ONC201, TIC10, Antagonist of dopamine receptor D2 (DRD2) and caseinolytic protease proteolytic subunit (ClpP), Radiation Therapy, Radiotherapy, Paxalisib, Inhibitor of the PI3K/AKT/mTOR pathway, GDC-0084, GDC0084, PI3K Inhibitor GDC-0084
University of California, San Francisco, The Chad-Tough Defeat DIPG Foundation, Mithil Prasad Foundation, Storm the Heavens Fund, National Institute of Neurological Disorders and Stroke (NINDS)
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent WHO Grade III Glioma, WHO Grade III Glioma
12/25
06/29
NCT06208657: Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer

Recruiting
1/2
82
Canada, RoW
Paxalisib, Irinotecan, Temozolomide, Pimasertib
Australian & New Zealand Children's Haematology/Oncology Group, Children's Cancer Institute Australia (CCIA), The Hospital for Sick Children, Medical Research Future Fund, Kazia Therapeutics Limited, Day One Biopharmaceuticals, Inc., C17 Council
Childhood Cancer, Childhood Solid Tumor, Childhood Brain Tumor, Recurrent Cancer, Refractory Cancer
12/30
12/35
ACTRN12624001340527: Paxalisib Plus Olaparib or Pembrolizumab/Chemotherapy in Advanced Breast Cancer

Not yet recruiting
1
24
 
Kazia Therapeutics, Kazia Therapeutics
Breast cancer
 
 
NCT05012670: Mass Balance Recovery, Metabolite Profile, and Metabolite Identification of [14C]-Paxalisib in Healthy Male Subjects

Completed
1
6
Europe
[14C]-Paxalisib Capsule, Phosphoinositide 3-kinase (PI3K) Inhibitor
Kazia Therapeutics Limited, Quotient Sciences
Healthy
03/23
01/24
NCT04192981: GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal Metastases

Hourglass Mar 2022 - Jun 2022 : Initial interim data from trial in combination with radiotherapy for brain metastases
Active, not recruiting
1
21
US
GDC-0084, whole brain radiation therapy radiation
Memorial Sloan Kettering Cancer Center, Kazia Therapeutics
Brain Metastases, Leptomeningeal Metastasis
12/25
12/25
EVT801 / Kazia
NCT05114668: Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours

Active, not recruiting
1
32
Europe
EVT801
Kazia Therapeutics Limited
Solid Tumor, Adult
10/24
10/24

Download Options